This Plain Language Summary of Publication article (PLSP) from Future Oncology, highlights results from the ASCEMBL trial, which compared the effectiveness and safety of asciminib to bosutinib in 233 adults with chronic myeloid leukemia (CML). Participants had previously undergone at least two treatments with tyrosine kinase inhibitors (TKIs) but stopped due to resistance or side effects. Researchers evaluated whether asciminib, a novel drug, provided better responses and fewer side effects than bosutinib. This summary focuses on findings reported at 24 weeks.

Visit the site using this link to read the article

This PLSP is based on an article called ‘A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs’ and was published in the Blood.

Visit Ash Publications using the link to read the original article.